Published in Pharmacoeconomics on January 01, 2015
Is personalized medicine a panacea for health management? Some thoughts on its desirability. Eur J Health Econ (2015) 1.08
Some economics on personalized and predictive medicine. Eur J Health Econ (2014) 0.97
Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges. Front Pharmacol (2016) 0.78
A time-and-motion approach to micro-costing of high-throughput genomic assays. Curr Oncol (2016) 0.78
Estimating the value of medical treatments to patients using probabilistic multi criteria decision analysis. BMC Med Inform Decis Mak (2015) 0.75
Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis. Pharmacoeconomics (2016) 0.75
"What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health (2017) 0.75
Integrating precision cancer medicine into healthcare-policy, practice, and research challenges. Genome Med (2016) 0.75
Personalized medicine in Europe: not yet personal enough? BMC Health Serv Res (2017) 0.75
Evaluating Frameworks That Provide Value Measures for Health Care Interventions. Value Health (2017) 0.75
Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. J Pers Med (2017) 0.75
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. Eur Urol (2017) 0.75
Evidence based medicine: what it is and what it isn't. BMJ (1996) 66.70
Consensus methods for medical and health services research. BMJ (1995) 17.94
Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health (2011) 5.12
Contingent valuation: what needs to be done? Health Econ Policy Law (2010) 2.83
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health (2013) 2.82
The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med (2010) 2.81
Heterogeneity in action: the role of passive personalization in comparative effectiveness research. Health Econ (2013) 2.04
The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA (2013) 1.93
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking. Cost Eff Resour Alloc (2012) 1.78
The behavioral economics of health and health care. Annu Rev Public Health (2013) 1.64
Personalized genomic medicine and the rhetoric of empowerment. Hastings Cent Rep (2012) 1.64
Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet (2009) 1.62
Modelling heterogeneity in patients' preferences for the attributes of a general practitioner appointment. J Health Econ (2007) 1.62
Value of information on preference heterogeneity and individualized care. Med Decis Making (2007) 1.49
Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics (2008) 1.46
Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ (2010) 1.43
What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics (2013) 1.41
The economic value of personalized medicine tests: what we know and what we need to know. Genet Med (2013) 1.40
Welfarism vs. extra-welfarism. J Health Econ (2007) 1.33
Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med (2008) 1.31
Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ (2012) 1.28
Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics (2010) 1.19
Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics (2014) 1.17
Understanding medication compliance and persistence from an economics perspective. Value Health (2008) 1.14
Economic analyses of human genetics services: a systematic review. Genet Med (2005) 1.10
Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care. J Health Econ (2011) 1.08
Patient empowerment: the need to consider it as a measurable patient-reported outcome for chronic conditions. BMC Health Serv Res (2012) 1.08
Personalized medicine and the practice of medicine in the 21st century. Mcgill J Med (2007) 1.06
Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Serv Res (2008) 1.05
Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. Value Health (2012) 1.05
Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess Health Care (2006) 1.03
The economic burden of incidentally detected findings. Radiol Clin North Am (2011) 1.03
Current methodological issues in the economic assessment of personalized medicine. Value Health (2013) 0.96
Current impact of gene technology on healthcare. A map of economic assessments. Health Policy (2006) 0.91
Points to consider in assessing and appraising predictive genetic tests. J Community Genet (2010) 0.91
Colon cancer screening practices and disclosure after receipt of positive or inconclusive genetic test results for hereditary nonpolyposis colorectal cancer. Cancer (2009) 0.90
Risk as an attribute in discrete choice experiments: a systematic review of the literature. Patient (2014) 0.89
Methods to elicit probability distributions from experts: a systematic review of reported practice in health technology assessment. Pharmacoeconomics (2013) 0.88
Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes. Value Health (2010) 0.88
The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer. BMC Health Serv Res (2014) 0.87
A review of economic evaluations of genetic testing services and interventions (2004-2009). Genet Med (2011) 0.86
Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. Health Policy (2013) 0.84
The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Making (2014) 0.84
The half-life of truth: what are appropriate time horizons for research decisions? Med Decis Making (2008) 0.83
The economics of diagnosis. Health Econ (2006) 0.81
Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. Pharmacoeconomics (2013) 0.81
Subgroup analyses of clinical effectiveness to support health technology assessments. Pharm Stat (2011) 0.80
When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Z Evid Fortbild Qual Gesundhwes (2013) 0.80
[Using value of information analysis in decision making about applied research. The case of genetic screening for hemochromatosis in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2012) 0.79
The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technol Assess (2009) 0.78
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med (2009) 13.42
The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. J Am Med Inform Assoc (2008) 4.77
A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. J Clin Epidemiol (2009) 4.48
Adapting clinical guidelines to take account of multimorbidity. BMJ (2012) 4.18
The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ (2010) 3.95
Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med (2014) 3.46
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol (2010) 2.89
Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care (2008) 2.64
Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke (2005) 2.29
Can we reliably benchmark health technology assessment organizations? Int J Technol Assess Health Care (2012) 2.27
German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health (2008) 2.20
A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics (2004) 2.15
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health (2012) 2.14
The impact of electronic patient portals on patient care: a systematic review of controlled trials. J Med Internet Res (2012) 2.11
Effects of thrombolysis during out-of-hospital cardiopulmonary resuscitation. Am J Cardiol (2005) 2.05
Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord (2003) 2.03
Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-detector computed tomography in a community-based cohort--consequences for progression studies. Eur J Radiol (2006) 1.99
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med (2012) 1.99
Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care (2005) 1.94
Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation (2010) 1.92
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol (2005) 1.88
Diagnostic performance of stress perfusion and delayed-enhancement MR imaging in patients with coronary artery disease. Radiology (2006) 1.85
Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol (2008) 1.82
Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care (2010) 1.70
Probabilistic computer model developed from clinical data in national mammography database format to classify mammographic findings. Radiology (2009) 1.65
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making (2012) 1.61
Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol (2011) 1.60
Mercury in breast milk - a health hazard for infants in gold mining areas? Int J Hyg Environ Health (2008) 1.58
High-resolution MR imaging of human atherosclerotic femoral arteries in vivo: validation with intravascular ultrasound. J Vasc Interv Radiol (2003) 1.57
Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: a meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting. Catheter Cardiovasc Interv (2003) 1.54
Postoperative troponin-T predicts prolonged intensive care unit length of stay following cardiac surgery. Crit Care Med (2004) 1.53
Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Res Treat (2013) 1.53
The Munich score: a clinical index to predict survival in ambulatory patients with chronic heart failure in the era of new medical therapies. J Heart Lung Transplant (2008) 1.51
Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ (2004) 1.48
A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process. Med Decis Making (2005) 1.45
Regression methods for cost-effectiveness analysis with censored data. Stat Med (2005) 1.44
Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. J Hepatol (2007) 1.44
Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics (2007) 1.44
Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: a comparison with coronary angiography and fractional flow reserve. Eur Heart J (2006) 1.41
Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. Radiology (2005) 1.39
A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. J Card Fail (2006) 1.36
Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics (2010) 1.35
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors. Oper Res (2010) 1.34
Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med (2008) 1.31
Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial. BMJ (2004) 1.30
Mercury as a serious health hazard for children in gold mining areas. Environ Res (2008) 1.30
Pharmacogenetics, the next challenge for pharmacy? Pharm World Sci (2006) 1.26
Breast cancer risk estimation with artificial neural networks revisited: discrimination and calibration. Cancer (2010) 1.26
Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison. Tob Control (2006) 1.25
Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. Value Health (2008) 1.24
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making (2012) 1.24
Long-term patency of internal mammary artery bypass grafts: relationship with preoperative severity of the native coronary artery stenosis. Circulation (2004) 1.24
Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin (2007) 1.23
Informatics in radiology: comparison of logistic regression and artificial neural network models in breast cancer risk estimation. Radiographics (2009) 1.23
A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. Eur J Radiol (2007) 1.21
New methodology for estimating the burden of infectious diseases in Europe. PLoS Med (2012) 1.21
Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. Circulation (2002) 1.19
Costs of inflammatory bowel disease in Germany. Pharmacoeconomics (2006) 1.19
Excess costs of dementia disorders and the role of age and gender - an analysis of German health and long-term care insurance claims data. BMC Health Serv Res (2012) 1.16
Health assessment of artisanal gold miners in Tanzania. Sci Total Environ (2009) 1.16
Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care (2008) 1.16
Costs of care for dementia patients in community setting: an analysis for mild and moderate disease stage. Value Health (2011) 1.15
EBM, HTA, and CER: clearing the confusion. Milbank Q (2010) 1.15
Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis (2005) 1.14
Medical care of type 2 diabetes in German disease management programmes: a population-based evaluation. Diabetes Metab Res Rev (2011) 1.13
Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics (2005) 1.13
Health-related quality of life in patients with narcolepsy. Sleep Med (2007) 1.11
A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J (2006) 1.11
Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 1.11
A logistic regression model based on the national mammography database format to aid breast cancer diagnosis. AJR Am J Roentgenol (2009) 1.11
What process attributes of clinical genetics services could maximise patient benefits? Eur J Hum Genet (2008) 1.11
The impact of ageing on hospital care and long-term care--the example of Germany. Health Policy (2004) 1.09
Mixed treatment comparisons using aggregate and individual participant level data. Stat Med (2012) 1.08
The Effect of Budgetary Restrictions on Breast Cancer Diagnostic Decisions. Manuf Serv Oper Manag (2012) 1.08
Patient empowerment: the need to consider it as a measurable patient-reported outcome for chronic conditions. BMC Health Serv Res (2012) 1.08
Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord (2007) 1.07
Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. Med Decis Making (2009) 1.07
Smoking and health-related quality of life in English general population: implications for economic evaluations. BMC Public Health (2012) 1.07
Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. Int J Technol Assess Health Care (2010) 1.06
Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. JACC Cardiovasc Interv (2011) 1.06
Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology (2014) 1.05
Health assessment of artisanal gold miners in Indonesia. Sci Total Environ (2009) 1.03
Regression estimators for generic health-related quality of life and quality-adjusted life years. Med Decis Making (2011) 1.02
Patient empowerment in clinical genetics services. J Health Psychol (2008) 1.01
Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord (2003) 1.01